BioCentury
ARTICLE | Clinical News

CK-2127107: Phase I started

April 8, 2013 7:00 AM UTC

Cytokinetics began a double-blind, placebo-controlled, crossover Phase I trial to evaluate single ascending-doses of oral CK-2127107 in healthy male volunteers. ...